Cepheid also received the rights to Cepheid’s MRSA patents for further development.
Cepheid and bioMerieux will together develop and commercialize an innovative line of sepsis test products on the GeneXpert® platform.
The product menu comprises both bacterial and fungal identification assays as well a series of genetic markers for antibiotic resistance. There is also the potential for hospital-acquired pneumonia applications.
Cepheid will be in charge of manufacturing, and bioMerieux will distribute the sepsis assays on an exclusive, worldwide basis.
In addition, bioMerieux has granted Cepheid a nonexclusive, worldwide license under the Hiramatsu patents on methicillin-resistant staphylococcus aureus (MRSA) for all applications. Cepheid will continue to develop, manufacture, and market MRSA products.